$MOBI

Tansey Casey M purchased $797K of MOBI

Tansey Casey M purchased 68,559 shares of Mobia Medical, Inc. (MOBI) at an average of $11.63 ($11.51–$12.53, $0.80M total) across 4 trades over 2026-08-13 to 2026-08-17.

Original reporting
SEC EDGAR · Tansey Casey M
Published Aug 18, 2026, 1:53 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 2:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MOBI
Bullish
medium confidence
Mentioned
$MOBI
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MOBIBullishLow
01

Why it matters

The newest information is the director’s open-market purchase details: 68,559 shares bought at $11.5073 to $12.5300, totaling $797,172.88, with post-transaction holdings of 301,891 shares.

02

Market read

Traders may treat the filing as a mild sentiment input, but it does not introduce new fundamentals like earnings, guidance, contracts, or regulatory actions.

03

What to watch

The article does not state whether the director’s purchase was part of a 10b5-1 plan (it says no), but it also provides no rationale, timing context, or follow-on selling behavior.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-17, covering buys from 2026-08-13 to 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Mobia Medical, Inc. (MOBI).

Company-level read

Ticker impact

$MOBIBullishMedium confidence
Context

Director Tansey Casey M bought 68,559 shares of Mobia Medical for about $797K across four trades, per a new Form 4 filing.

Expected impact

Near-term impact is likely limited; any effect would be sentiment-driven rather than a re-rating catalyst.

Evidence & confidence

The filing provides transaction size, dates, and weighted average price, but no accompanying operational update, guidance, or deal terms.

Market effects

No sector-wide signal is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (compensation, diversification, or planned liquidity needs) and may not reflect a change in business outlook.

Key entities

  • Mobia Medical, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tansey Casey M

    Director who executed the open-market purchase transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MOBIHigh

Mobia Medical stock jumps on stroke guideline inclusion

Mobia Medical Inc (MOBI) shares rose 7.2% premarket after the American Heart Association included its paired vagus nerve stimulation in 2026 stroke rehabilitation guidelines. The Vivistim Paired VNS System is the only FDA-approved system for this treatment, which may improve upper-limb function. Stroke is a leading cause of long-term disability in the U.S.

$MOBIMedAI 8/10

Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical (MOBI) reported Q2 2026 revenue of $13.5M, up 102% YoY, driven by Vivistim system adoption. Full-year guidance set at $54M-$56M. Net loss was $21M, with cash reserves of $177.1M post-IPO. Management plans to expand active territories and target 1,500 U.S. stroke centers.

$MOBIMed

Mobia Medical, Inc. (MOBI): Results of Operations and Financial Condition

Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial re

$MOBIMedAI 8/10

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.